Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.89 |
| ▸ | CHAT | P28329 | 2/20 | 0.85 |
| ▸ | EP300 | Q09472 | 3/20 | 0.84 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.84 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290381 | 1.00 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL4287977 | 0.97 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL18038084 | 0.97 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL27571436 | 0.97 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL26116845 | 0.97 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL502465 | 0.97 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL4368641 | 0.97 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL27877871 | 0.97 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL25252 | 0.97 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| Charcoal, Activated SCHEMBL1644250 | 0.96 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745163-B2 | contacting sample with a reagent comprising a thiol-containing compound, a halo-acetyl-CoA or a halo-acetyl-pantetheine, and an acetyltransferase under conditions suitable for acetyltransferase enzyme activity then identifying a substrate that has formed a base-stable covalent bond to the reagent | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-06-29 | — | — | US | claimed |
| EP-1789029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024489-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2005044077-A2 | ASSAY FOR ACETYLTRANSFERASES AND ACETYLTRANSFERASE SUBSTRATES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2005-05-19 | — | — | WO | claimed |
| CN-109689051-B | Use of inhibitors of mitochondrial activity for the treatment of acute myeloid leukemia with poor prognosis | 蒙特利尔大学 | 2022-03-29 | — | — | CN | disclosed |
| US-11008362-B2 | Malonyl-coenzyme A mimics as fatty acid synthase inhibitors and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2021-05-18 | — | — | US | disclosed |
| US-10851393-B2 | KAS-III free FA synthesis | WILLIAM MARSH RICE UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | UNIVERSITE DE MONTREAL (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | Université de Montréal (CA) | 2019-06-27 | — | — | US | disclosed |
| EP-3493802-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | Université de Montréal (CA) | 2019-06-12 | — | — | EP | disclosed |
| US-10186410-B2 | Mass spectrometer, system comprising the same, and methods for determining isotopic anatomy of compounds | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-01-22 | — | — | US | disclosed |
| EP-1789029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | disclosed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024489-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005044077-A2 | ASSAY FOR ACETYLTRANSFERASES AND ACETYLTRANSFERASE SUBSTRATES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008362-B2 | Malonyl-coenzyme A mimics as fatty acid synthase inhibitors and methods of use | COASY, FASN, FADS1 | NAA50 595/4885CHAT 2856/4885EP300 900/4885 |
| US-20200188361-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | NPM1, TFAM, NDUFAF1 | NAA50 1701/4885CHAT 4654/4885EP300 1930/4885 |
| US-20190192488-A1 | USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA | IDH2, TFAM, NUTF2 | NAA50 1723/4885CHAT 4796/4885EP300 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.